You dont have javascript enabled! Please download Google Chrome!

The FDA calendar tracks upcoming PDUFA drug approval dates, FDA Advisory Committee meetings, and trading notes. Click on the Categories drop down on the top left side of the calendar to turn PDUFA, FDA Advisory Committee (Adcom), and trade notes, either on or off. Each overlay toggles between on and off when it is clicked. If you unselect all overlays, you will see the default view which is all calendar events.

  

To change the view of the calendar, click on the Month drop down on the top right side of the calendar.

  
Catalyst swing trading is one of many tools used to “crack the code” of profitable stock market endeavors. The most basic aspect of catalyst trading is to foresee coming “hype” within a stock or industry, buy in advance, and sell into the exponential rise. If you plan to hold through the event, only hold onto what you can afford to lose; even when the the news in positive, the hype is over and price action can turn negative. Aka “sell the news.”
  
Use this calendar to search and share upcoming catalyst swing trades. When adding an event to the calendar, please remember to link all sources along with the correct catalyst subcategory and pre-event highlights (if any). This will help others to quickly filter/review it as a potential trade.
  

Trading Biotech Stocks With Upcoming Catalysts

  
Catalyst events that move stocks are:
-Earnings
-FDA/BioTech
-Fed/Gov/Economic Data
-IPOs/Miscellaneous
-Presentations/Conferences – (Any event tickers are hyping into)
  
The idea is to start tracking a stock’s price performance about a month before a PDUFA or Phase 3 event. Ideally, you want the biotech stock to meet the following criteria:
-50%+ Analyst Price Target
-Action Heating Up
-Float Short 10%+
-Good Technical Setup
-Institutional Ownership 20%+
– Low Chance of Dilution/Cash on Hand
– Low Float/Small Cap
  
Please keep in mind that the goal is to play the run up or the news “hype” of the PDUFA or Phase 3 event, NOT hold through it. As soon as the biotech stock runs up, you sell and book profits. Do not hold through the event.
  

You can search the entire FDA calendar by using the search box below.

Search
Generic filters
Exact matches only
Search in title
Search in content
Search in excerpt
Search in comments
Filter by Custom Post Type
Sun Mon Tue Wed Thu Fri Sat
1
AZN Tagrisso FLAURA
AZN Tagrisso FLAURA
Jun 1 all-day
AZN Tagrisso FLAURA
(AZN) First-line lung cancer. Phase 3 data released July 27, 2017. sNDA awarded priority review on noted December 18, 2017. No PDUFA date given but should be sometime in Q2 2018.
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
TEVA Fremanezumab
TEVA Fremanezumab
Jun 16 all-day
TEVA Fremanezumab
Fremanezumab Migraine PDUFA June 16, 2018.
17
18
AGN ESMYA (ulipristal acetate)
AGN ESMYA (ulipristal acetate)
Jun 18 all-day
AGN ESMYA (ulipristal acetate)
(AGN) Uterine Fibroids. Phase 3 data released January 18, 2017, endpoints met. No PDUFA date given so June 18, 2018 guestimate. https://www.allergan.com/News/News/Thomson-Reuters/Allergan-Announces-that-the-FDA-Accepts-New-Drug-A
VRX IDP-118
VRX IDP-118
Jun 18 all-day
VRX IDP-118
(VRX) Psoriasis. PDUFA date June 18, 2018.
19
20
21
22
NVS Tafinlar (dabrafenib) and Mekinist (trametinib)
NVS Tafinlar (dabrafenib) and Mekinist (trametinib)
Jun 22 all-day
NVS Tafinlar (dabrafenib) and Mekinist (trametinib)
(NVS) Melanoma with BRAF V600E or V600K mutations. Priority review received December 22, 2017. No PDUFA date given. Six month priority review estimated date of June 22, 2018.
23
SCPH Furoscix
SCPH Furoscix
Jun 23 all-day
SCPH Furoscix
(SCPH) Heart failure. PDUFA June 23, 2018. Phase 3 trial did not meet FDA’s prespecified performance criteria.
24
25
AKAO Plazomicin
AKAO Plazomicin
Jun 25 all-day
AKAO Plazomicin
(AKAO) Complicated urinary tract infections. Phase 3 data released December 12, 2016 – primary endpoint met. PDUFA date under priority review June 25, 2018.
26
27
GWPH Epidiolex
GWPH Epidiolex
Jun 27 all-day
GWPH Epidiolex
(GWPH) Dravet Syndrome and Lennox-Gastaut syndrome. PDUFA date under priority review June 27, 2018. http://ir.gwpharm.com/releasedetail.cfm?ReleaseID=1052733
28
29
30
ARRY Binimetinib – COLUMBUS
ARRY Binimetinib – COLUMBUS
Jun 30 all-day
ARRY Binimetinib - COLUMBUS
(ARRY) BRAF mutant melanoma cancer. Phase 3 data released September 26, 2016 met primary endpoint. PDUFA date June 30, 2018. http://investor.arraybiopharma.com/phoenix.zhtml?c=123810&p=irol-newsArticle&ID=2330521
Go top

This website uses cookies to guarantee the best experience for the user. If you continue browsing, we consider that you agree to their use. For more information click here.

error: